Biological agents in rheumatology: advantages, limitations, and safety profile of molecularly targeted therapy

Abstract

Over the past decades, biological agents have rapidly evolved in rheumatology, fundamentally transforming therapeutic strategies for autoimmune and inflammatory diseases. This article provides a comprehensive scientific and theoretical analysis of the molecular mechanisms, clinical efficacy, safety outcomes, and economic aspects of biological therapies used in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and other systemic inflammatory disorders. Biological agents selectively target cytokines and immune cell receptors, thereby blocking key mediators involved in disease pathogenesis. Statistical data indicate that approximately 60–70% of patients with rheumatoid arthritis achieve clinical remission or low disease activity with tumor necrosis factor-alpha (TNF-α) inhibitors. Interleukin-6 receptor antagonists and B-cell–targeted therapies demonstrate high efficacy in severe and refractory cases. However, limitations such as infectious complications, immunogenicity, potential malignancy risk, and high treatment costs remain important considerations. This paper discusses not only the therapeutic benefits of biologic agents but also emphasizes safety monitoring strategies, individualized treatment approaches, and pharmacoeconomic evaluations. The accumulated evidence suggests that biologic therapies play a crucial role in the management of rheumatic diseases, yet strict adherence to clinical safety protocols is essential to optimize therapeutic outcomes and minimize potential risks.